James H Woods
Overview
Explore the profile of James H Woods including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Free R, Nilson A, Boldizsar N, Doyle T, Rodriguiz R, Pogorelov V, et al.
ACS Pharmacol Transl Sci
. 2023 Jan;
6(1):151-170.
PMID: 36654757
We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity - ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition...
2.
Johnson C, Kangas B, Jutkiewicz E, Winger G, Bergman J, Coop A, et al.
J Pharmacol Exp Ther
. 2021 Mar;
377(3):336-345.
PMID: 33712507
The cholinergic nervous system has been implicated in mood disorders, evident in the fast-onset antidepressant effects of scopolamine, a potent muscarinic antagonist, in clinical studies. One prominent disadvantage of the...
3.
Winger G, Jutkiewicz E, Woods J
Behav Pharmacol
. 2020 Jan;
31(4):359-367.
PMID: 31922966
This study aimed to use central and peripheral assays to compare the effects of the muscarinic antagonist scopolamine with those of a novel muscarinic antagonist, L-687,306 [(3R,4R)-3-(3-cyclopropyl-1,2,4,oxadiazol[5-yl]-1-azabicyclo[2.2.1]heptane. Groups of rats...
4.
Gerak L, Maguire D, Woods J, Husbands S, Disney A, France C
J Pharmacol Exp Ther
. 2018 Nov;
368(2):229-236.
PMID: 30463875
One consequence of the ongoing opioid epidemic is a large number of overdose deaths. Naloxone reverses opioid-induced respiratory depression; however, its short duration of action limits the protection it can...
5.
Maguire D, Gerak L, Woods J, Husbands S, Disney A, France C
J Pharmacol Exp Ther
. 2018 Nov;
368(1):88-99.
PMID: 30401680
Opioid abuse remains a serious public health challenge, despite the availability of medications that are effective in some patients (naltrexone, buprenorphine, and methadone). This study explored the potential of a...
6.
Reilly M, Berndt S, Woods J
Behav Anal (Wash D C)
. 2017 Jun;
16(4):200-209.
PMID: 28584876
The present study investigated the role of drug-paired stimuli in controlling the behavior of rhesus monkeys. Systematic observations were made with nine monkeys who had a history of drug self-administration;...
7.
Woods J, Takada K
Psychopharmacology (Berl)
. 2016 Oct;
233(23-24):3827-3828.
PMID: 27709250
No abstract available.
8.
Saccone P, Lindsey A, Koeppe R, Zelenock K, Shao X, Sherman P, et al.
J Pharmacol Exp Ther
. 2016 Sep;
359(2):366-373.
PMID: 27625351
The goal of this study was to evaluate the effects of intranasally administered opioids in rhesus monkeys using the tail-withdrawal assay, and to correlate these effects with measures of receptor...
9.
Saccone P, Zelenock K, Lindsey A, Sulima A, Rice K, Prinssen E, et al.
J Pharmacol Exp Ther
. 2016 Jan;
357(1):17-23.
PMID: 26801398
Nociceptin/orphanin FQ receptor (NOP) agonists have been reported to produce antinociceptive effects in rhesus monkeys with comparable efficacy to μ-opioid receptor (MOP) agonists, but without their limiting side effects. There...
10.
Bertz J, Jackson E, Barron D, Woods J
Behav Pharmacol
. 2015 Nov;
27(2-3 Spec Issue):137-47.
PMID: 26580131
Opioid-conditioned reinforcement is thought to exacerbate opioid abuse and dependence. Sex/gender can influence opioid abuse behaviors, but the effects of sex/gender on opioid-conditioned reinforcement, specifically, are unclear. In this study,...